Understanding treatment outcomes in lymphoma-related hemophagocytic lymphohistiocytosis
Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
University of Alabama at Birmingham · NCT05898477
This study looks at how people with lymphoma who develop a serious condition called hemophagocytic lymphohistiocytosis are treated and what the outcomes are, to find better ways to help them survive.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Sex | All |
| Sponsor | University of Alabama at Birmingham (other) |
| Locations | 1 site (Birmingham, Alabama) |
| Trial ID | NCT05898477 on ClinicalTrials.gov |
What this trial studies
This observational study aims to describe the clinical features, laboratory parameters, treatments, and outcomes of patients with lymphoma who develop hemophagocytic lymphohistiocytosis (HLH). It is a retrospective, multi-institutional analysis that seeks to identify potential therapeutic strategies to enhance overall survival for these patients. By examining data from individuals presenting with HLH in the context of lymphoma, the study hopes to provide insights into effective management approaches.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with lymphoma who meet specific HLH diagnostic criteria.
Not a fit: Patients who develop HLH more than one month after their lymphoma diagnosis or those with incomplete treatment documentation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and better survival rates for patients with lymphoma-associated HLH.
How similar studies have performed: While this study focuses on a specific patient population, similar observational studies have shown promise in identifying effective treatment strategies for HLH in various contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with lymphoma that are fulfilling at least one of the following: A. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25\>3,900 U/mL and ferritin\>1,000 ng/mL) Exclusion Criteria: * Patients developing HLH\> 1 month after lymphoma diagnosis (for aggressive lymphomas) * Patients with incomplete treatment and response documentation
Where this trial is running
Birmingham, Alabama
- University of Alabama at Birmingham — Birmingham, Alabama, United States (RECRUITING)
Study contacts
- Principal investigator: Gaurav Goyal, MD — University of Alabama at Birmingham
- Study coordinator: Gaurav Goyal, MD
- Email: ggoyal@uabmc.edu
- Phone: 205-934-1816
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lymphoma, Hemophagocytic Lymphohistiocytoses